GSK and Alfasigma have signed a licensing agreement granting Alfasigma worldwide exclusive rights to develop, manufacture and commercialise linerixibat, an investigational IBAT inhibitor for the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results